title: A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
abstract: BACKGROUND
  Bevacizumab plus doublet chemotherapy has become one of the standard treatments for patients with metastatic colorectal cancer (mCRC). We have investigated the efficacy and safety of bevacizumab plus capecitabine and oxaliplatin as first-line chemotherapy for Korean patients with mCRC.
  
  
  METHODS
  Patients were treated with bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m on day 1 and capecitabine 2000 mg/m/d on days 1 to 14. After 9 cycles, patients were entered into the maintenance treatment, consisting of bevacizumab and capecitabine. Treatment was repeated every 3 weeks and response was evaluated every 2 cycles.
  
  
  RESULTS
  Of the 49 patients (median age, 57 y), 29 (59%) had primary tumors in the colon, and 31 (63%) had metastases in 2 or more organs. Overall response rate was 71.4% (95% confidence interval [CI], 58.7%-84.1%), median progression-free survival was 10.4 months (95% CI, 8.2-12.5 mo), and median overall survival was 20.0 months (95% CI, 16.7-23.4 mo). Frequent grade 3 toxicities included neuropathy (9, 18.4%), neutropenia (8, 16.3%), diarrhea (6, 12.2%), and thrombocytopenia (3, 6.1%). Bevacizumab-related grade 3 or 4 toxicities included proteinuria (1, 2.0%) and bowel perforation (1, 2.0%).
  
  
  CONCLUSIONS
  Bevacizumab plus capecitabine and oxaliplatin was well tolerated and showed promising antitumor activity in Korean patients with mCRC.
authors.affiliation: *Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul ‡Department of Internal Medicine, Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul §Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul ¶Department of Internal Medicine, Samsung Medical Center, Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Seoul †Center for Colorectal Cancer, National Cancer Center, Research Institute and Hospital, Goyang ∥Department of Internal Medicine, Division of Hematology and Medical Oncology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
authors.forename: Yong Sang
authors.initials: YS
authors.lastname: Hong
authors.forename: Sung Sook
authors.initials: SS
authors.lastname: Lee
authors.forename: Kyu-pyo
authors.initials: KP
authors.lastname: Kim
authors.forename: Jae-Lyun
authors.initials: JL
authors.lastname: Lee
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
authors.forename: Sang Joon
authors.initials: SJ
authors.lastname: Shin
authors.forename: Joong Bae
authors.initials: JB
authors.lastname: Ahn
authors.forename: Kyung Hae
authors.initials: KH
authors.lastname: Jung
authors.forename: Seock-Ah
authors.initials: SA
authors.lastname: Im
authors.forename: Tae-You
authors.initials: TY
authors.lastname: Kim
authors.forename: Jee Hyun
authors.initials: JH
authors.lastname: Kim
authors.forename: Young Suk
authors.initials: YS
authors.lastname: Park
authors.forename: Tae Won
authors.initials: TW
authors.lastname: Kim
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D053208:Kaplan-Meier Estimate; D060046:Maintenance Chemotherapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011446:Prospective Studies; D056910:Republic of Korea; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil